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Abstract
Background: It is known that steroid usage and alcohol abuse are major etiological factors in the
development of avascular necrosis (AVN), a bone disease that produces osteonecrosis of the
femoral head. The facilitation of fat biosynthesis by steroids and alcohol disrupts the blood supply
into the femoral head. SREBP-2 plays a central role in the maintenance of lipid homeostasis through
stimulating expression of genes associated with cholesterol biosynthetic pathways. The aim of this
study was to examine the association between the polymorphisms of the SREBP-2 gene and AVN
susceptibility in the Korean population.
Methods: Four single nucleotide polymorphisms (SNP) in the SREBP-2 gene, IVS1+8408 T>C
(rs2267439), IVS3-342 G>T (rs2269657), IVS11+414 G>A (rs1052717) and IVS12-1667 G>A
(rs2267443), were selected from public databases and genotyped in 443 AVN patients and 273
control subjects by using single-based extension (SBE) genotyping.
Results: The minor allele (C) frequency of rs2267439 showed a significant protective effect on
AVN (P = 0.01, OR; 0.75, 95% CI; 0.604–0.935), and the genotype frequencies of this polymorphism
were also different from the controls in all alternative analysis models (P range, 0.009–0.03, OR;
0.647–0.744). In contrast, rs1052717 and rs2267443 polymorphisms were significantly associated
with AVN risk. Further analysis based on pathological etiology showed that the genotypes of
rs2267439, rs1052717 and rs2267443 were also significantly associated with AVN susceptibility in
each subgroup.
Conclusion: This study is the first report to evaluate the association between SREBP-2 gene
polymorphisms and the susceptibility of AVN in the Korean population.
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Background
Avascular necrosis (AVN), also known as osteonecrosis of
the femoral head (ONFH), is a devastating bone disease
that develops symptoms of articular destruction and bone
collapse of the femoral head due to a disturbance in the
supply of blood [1]. This disease mainly occurs in middle
aged men, between 30 and 50 years of age. The patho-
genic factor of AVN is not definite, but many previous
studies have suggested that long term steroid usage [1-5]
and alcohol abuse [6,7] are associated with AVN, and in
some case it can also be idiopathic. These factors have a
harmful influence on oxygen and nutrient supply to the
bone through blood vessels in direct or indirect pathways.
Steroid administration and alcohol abuse induce an
increase of fatty vesicles in the circulation of the blood,
causing fat embolism and increased lipid precipitation in
osteocytes within the femoral head. Some previous exper-
iments using animal models verified that alcohol facili-
tates the overgrowth of fat cells and inhibits osteogenesis
in the femoral head [8]. As a result, these changes obstruct
the flow of blood and induce intraosseous hypertension,
thus leading to bone collapse.
Sterol regulatory element binding transcription proteins
(SREBPs) which belong to the basic helix-loop-helix fam-
ily of transcription factors have been associated with lipo-
genesis, adipocyte development and cholesterol
homeostasis [9]. Three members of the SREBP family,
SREBP-1a, SREBP-1c and SREBP-2, have been identified to
date [10]. SREBP-1a contributes to cholesterol and fatty
acid metabolisms, and SREBP-1c regulates expression of
certain genes associated with biosynthesis of fatty acid
[11]. SREBP-2, which is encoded by a separate gene on
human chromosome 22, plays a central role in the main-
tenance of lipid homeostasis through stimulating expres-
sion of genes associated with the cholesterol biosynthetic
pathways [12]. SREBP-2 exists in the membrane of endo-
plasmic reticulum forming a complex with SREBP cleav-
age activating protein (SCAP) [13]. When cholesterol is
deficient in cells, SCAPs transport SREBP-2 from endo-
plasmic reticulum to the Golgi complex, where the pro-
teins are cleaved by two protease known as Site-1 protease
(S1P) and Site-2 protein (S2P) and are maturated to a sol-
uble transcription factor to stimulate the expression of the
target genes. The target genes of maturated SREBP-2
encode enzymes with important roles in the synthesis and
uptake pathway of cholesterol and triglyceride [14].
In this study, we hypothesized that SREBP-2 activity is
responsible for the development of AVN and that the var-
iants of SREBP-2 gene are associated with the susceptibil-
ity to AVN. To test this hypothesis, four SREBP-2 single
nucleotide polymorphisms (SNPs) which show high het-
erozygosities in Asian populations, especially Han Chi-
nese and Japanese, were selected from the public
database, and their association with susceptibility to AVN
in the Korean population was evaluated.
Methods
Subjects
Blood samples and information were obtained from 443
unrelated patients with AVN (366 men, 77 women; age:
49.7 ± 13.3) and 273 control subjects (206 men, 67
women; age: 52.1 ± 10.6) visiting Kyungpook National
University Hospital (Daegu, Korea) between 2002 and
2006. Diagnosis was established by the evidence of symp-
tomatic AVN using anteroposterior, lateral-pelvic radio-
graphs and magnetic resonance imaging (MRI) in stage 1
of association research circulation osseous (ARCO) classi-
fication system, and by plain radiographs in stages 2, 3
and 4. Patients with a demonstrable history of direct
trauma or with a possible combination of causes were
excluded. Based on etiological factors, the patients were
subgrouped into idiopathic (181 cases), alcohol-induced
(206 cases) and steroid-induced (56 cases) groups. Ster-
oid-induced AVN was defined by a history of taking 1800
mg prednisolone or an equivalent over 4 weeks with
nephritic syndrome, systemic lupus erythematosus, rheu-
matoid arthritis, allergic asthma, or organ transplantation
[15]. Alcohol-induced AVN was defined by the consump-
tion of more than 400 ml of pure ethanol per week, or by
the observation of alcohol induced fatty liver and liver cir-
rhosis. Control subjects were recruited from spouses of
the patients and the general population and were consid-
ered normal if they had no hip pain and if anteroposterior
and frog-leg lateral pelvic radiographs did not reveal any
lesions with sclerotic margins or subchondral collapse
consistent with AVN. All individuals provided informed
consent for their participation in the study, and this
project was approved by our Institutional Review Board.
Polymerase chain reaction (PCR) amplification
Genomic DNA was isolated from peripheral blood leuko-
cytes using a FlexiGene DNA Kit (QIAGEN, Valencia, CA,
USA). All PCR reactions were performed in a 25 μl volume
containing 1× PCR buffer (Solgent, Korea), 10 mM deox-
ynucleotide triphosphate (dNTP), 10 pmol each of for-
ward and reverse oligonucleotide primer, 1 U/μl Taq DNA
polymerase (Solgent, Korea), and 25 ng genomic DNA.
The parameters for PCR consisted of a denaturation cycle
at 95°C for 15 min, followed by 35 cycles at 95°C for 20
sec, 55–57°C for 40 sec, 72°C for 1 min, a final extension
cycle at 72°C for 5 min, and a stabilization step at 4°C.
PCR was performed using a PTC-200 thermal cycler and
an iCycler™ Thermal cycler (BIO-RAD). For purification of
the PCR products, an ExoSAP IT Kit (USB Corp., Cleve-
land, OH, USA) was used.BMC Medical Genetics 2008, 9:94 http://www.biomedcentral.com/1471-2350/9/94
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Genotype analysis
Genotyping was performed by the single-based extension
(SBE) method with a SNaPshot Kit (Applied Biosystems
Corp., Foster City, CA, USA). The SBE reaction mixture
was prepared according to the manufacturer's instruc-
tions. The primer extension reaction was performed in 25
cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 30
sec. To resolve the excess primers, 1 unit of shrimp alka-
line phosphatase (USB Corp., Cleveland, OH, USA) was
added to the reaction mixture, and the mixture was incu-
bated at 37°C for 60 min, followed by 15 min at 80°C for
enzyme inactivation. The loading solution containing an
injection marker was added to inactivate the SNaPshot
reaction mixtures according to the recommendations of
the manufacturer. Genotype scanning was performed
using an ABI 3130 × l genetic analyzer, and the resulting
files were analyzed by using Gene Mapper software pro-
gram (Applied Biosystems Corp., Foster City, CA, USA).
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was tested to
determine significant deviation of the genotype frequency
from each single nucleotide polymorphism (SNP) by
using the χ2 test. Logistical regression analyses were used
to calculate the odds ratios (ORs), 95% confidence inter-
vals (CIs) and haplotypes, controlling for sex and age as
covariates, with three alternative models (codominant,
dominant and recessive). The linkage disequilibrium
(LD) between loci was measured using the absolute value
of Lewontin's D' (|D'|) and r2 [16]. Haplotypes of the
SREBP-2  gene were analyzed using Haploview version
3.32 http://www.broad.mit.edu/haploview/haploview
based on the expectation maximization (EM) algorithm
[17]. All analyses were two-tailed, and a P value < 0.05 was
considered statistically significant. Statistics were per-
formed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
To investigate the association of SREBP-2 gene polymor-
phisms with AVN, we selected four intronic SNPs,
rs2267439, rs2269657, rs1052717 and rs2267443, from
public databases by considering their allele frequencies
and positions, and analyzed these polymorphisms in 443
AVN patients and 273 control subjects. LD coefficients
(|D'|) and r2  were calculated, and rs2269657 and
rs1052717 demonstrated tight LD (Fig. 1A and 1B). The
haplotypes and their frequencies in the LD block between
rs2269657 and rs1052717 are showed in Figure 1C.
The genotype frequencies of all the polymorphisms were
in accordance with Hardy-Weinberg equilibrium in both
cases and control groups (Table 1). The P values of each
polymorphism were analyzed by logistic analysis with
respect to a comparison between AVN patients and the
controls. As shown in Table 2, the allele and genotype fre-
quencies of rs2267439 in patients were significantly dif-
ferent from those in the controls. The minor allele (C)
frequency of rs2267439 showed a significant protective
effect on AVN (P = 0.01, OR; 0.75, 95% CI; 0.604–0.935),
and the genotype frequencies of this polymorphism were
also different from the controls in all alternative analysis
models (P range; 0.009 – 0.03, OR; 0.647–0.744). In con-
trast to the characteristics of polymorphism rs2267439,
rs1052717 and rs2267443 polymorphisms were signifi-
cantly associated with the risk of AVN. The AA genotype
frequency in rs1052717 was higher in patients when cal-
culated using the recessive model (P = 0.04, OR; 1.8, 95%
CI; 1.034–3.120). The rs2267443 allele and genotype fre-
quencies showed a significantly higher risk factor in AVN
patients compared with those in controls with P values
0.04 (OR; 1.27, 95% CI; 1.006–1.590) and 0.04 (OR;
1.26, 95% CI; 1.003–1.579) in the codominant model.
Though the P value of rs2267443 genotype frequency in
the recessive model was slightly greater than 0.05, it
showed the tendency of weak association with the risk of
AVN development. No differences in the frequencies of
the allele and genotypes were seen in patients and the
controls in the case rs2269657 polymorphisms.
Further analysis based on pathological etiologies such as
idiopathic, alcohol-induced or steroid-induced showed
that the allele and genotype frequencies of rs2267439 in
the idiopathic subgroup were significantly different than
those in the controls, suggesting that this polymorphism
had a protective effect on AVN development (Table 3).
However, rs1052717 and rs2267443 polymorphisms
were significantly associated with increased risk of AVN in
the idiopathic and alcohol subgroup, respectively.
Based on LD coefficients, haplotype frequencies were
compared between the patients and the controls. As
shown in Table 4, the GG haplotype frequencies in
patients were significantly lower than those in the con-
trols in the dominant and codominant models (P range;
0.02–0.03, OR; 0.67–0.78). In contrast, the GA haplotype
demonstrated a risk factor to AVN in a recessive model (P
value; 0.008, OR; 2.24, 95% CI; 1.231–4.069).
Discussion
Numerous studies about bone necrosis have suggested
that many factors, such as steroid usage, alcoholism,
infections, coagulation defects, and some autoimmune
diseases are closely related with AVN susceptibility. How-
ever, etiological and pathological mechanisms of AVN
have not yet been thoroughly investigated. In the patho-
genic mechanisms suggested to date, a vascular hypothe-
sis is considered to be most persuasive. It assumes that the
combined effect of many metabolic factors that induce the
interception of blood flow in the femoral head raises
intraosseous pressure leading to osteonecrosis and even-BMC Medical Genetics 2008, 9:94 http://www.biomedcentral.com/1471-2350/9/94
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Linkage disequilibrium coefficients and haplotypes of SREBP-2 polymorphisms A. Linkage disequilibrium (LD) among SREBP-2  polymorphisms Figure 1
Linkage disequilibrium coefficients and haplotypes of SREBP-2 polymorphisms A. Linkage disequilibrium (LD) 
among SREBP-2 polymorphisms.B. LD coefficients (| D'| and r2) between SREBP-2 polymorphisms. C. Haplotypes and 
their frequencies between two linked SNPs, rs2269657 and rs1052717, in a LD block.
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tual bone collapse [18-21]. In particular, steroid usage
and alcoholism increase the fat volume in bone marrow
and blood, causing the interruption of blood flow and
deposition of fat in the femoral head. Numerous studies
have identified that hyperlipidemia in the femoral head
induced by steroid and alcohol use is associated with AVN
[22-26]. However, the fact that the frequency of AVN
occurrence is not always in proportion to the period and
concentration of steroid use and alcohol intake indicates
that individual disparity of susceptibility for these factors
is an important element of the disease [27].
The SREBP-2 gene encodes the membrane-bound tran-
scription factor controlling the expression of genes for the
regulation of cholesterol homeostasis [12]. Its protein
product, SREBP-2, regulates several genes for sterol home-
ostasis by recognizing the cholesterol levels in the cell,
and generally producing negative feedback [28]. Consid-
ering the importance of SREBP-2 in the regulation of lipid
metabolism, it is more likely that AVN susceptibility may
be associated with SREBP-2 polymorphisms.
The results of our study provide evidence of an association
between SREBP-2  gene polymorphisms and AVN. One
polymorphism was found to be protective, and two were
found to increase the risk of the disease (Table 2). Moreo-
ver, the protective effect of rs2267439 was associated with
the idiopathic subgroup, which was in contrast to risk fac-
tor rs1052717 and rs2267443 in the alcohol-induced and
idiopathic groups, respectively. Mont et al. (1995)
reported that most idiopathic AVN originates from
increased alcohol consumption, and Wang et al (2003)
showed alcohol-induced adipogenesis as a model for the
development of osteonecrosis, especially in patients with
long-term and excessive use of alcohol [8,29]. In addition,
haplotype GA showed as a risk factor for AVN, but AVN
risk for haplotype GG in the patient group was signifi-
cantly lower than in the control group. This result suggests
that the rs2269657 G allele might provide a protective
effect against AVN as a result of interaction with
rs1052717, even though rs2269657 alone was not associ-
ated with the disorder. Along with genetic factors, chronic
alcohol consumption may promote the malfunction of
SREBP-2  which is directly or indirectly related to the
development of AVN. Therefore, our study suggests that
SREBP-2 gene polymorphisms may be one of the most
important genetic factors in AVN susceptibility in the
Korean population. To further substantiate this hypothe-
sis, functional studies of SREBP-2 ethanol regulation are
required, and the polymorphisms analyzed in this study
may contribute to further studies regarding SREBP-2 func-
tion and AVN development.
Table 1: Frequencies of SREBP-2 polymorphisms in AVN and normal subjects
Loci Position rs# Genotype MAF Heterozygosity HWE
Control Case all Alcohol Idiopathic Steroid
IVS1+8408 T>C Intron1 rs2267439 TT CT CC N 0.714 0.619 0.653 1 0.428
AVN 159 218 66 443 0.395 0.492
CTL 77 138 55 270 0.459 0.511
IVS3-342 G>T Intron2 rs2269657 GG GT TT N 0.637 0.71 0.469 1 1
AVN 241 149 32 422 0.263 0.353
CTL 146 107 16 269 0.258 0.398
IVS11+414 G>A Intron11 rs1052717 GG AG AA N 0.301 0.331 0.334 0.184 0.237
AVN 202 186 53 441 0.331 0.422
CTL 132 120 19 271 0.292 0.443
IVS12-1667 G>A Intron11 rs2267443 GG AG AA N 0.891 0.267 1 0.077 1
AVN 169 192 69 430 0.384 0.447
CTL 116 121 29 266 0.337 0.455B
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Table 2: Association of SREBP-2 gene polymorphisms between the AVN patients and controls
Loci Sub-group Genotype Allele 2 vs. 1 Codominant Heterozy Dominant Recessive
11 12 22 MAF (11 vs 12 vs 22)* 12 + 22 vs. 11 22 vs. 11 + 12
OR (95% CI) P† OR (95% CI) P† OR (95% CI) P† OR (95% CI) P†
IVS1+8408 T>C TT CT CC
(rs2267439) CTL 77 138 55 0.459
AVN 159 218 66 0.395 0.751
(0.604–0.935)
0.010 0.744
(0.595–0.930)
0.009 0.702
(0.504–0.978)
0.036 0.647
(0.433–0.964)
0.033
IVS3-342 G>T GG GT TT
(rs2269657) CTL 146 107 16 0.258
AVN 241 149 32 0.263 1.069
(0.835–1.369)
0.596 1.070
(0.834–1.372)
0.595 1.039
(0.762–1.415)
0.810 1.305
(0.697–2.442)
0.406
IVS11+414 G>A GG AG AA
(rs1052717) CTL 132 120 19 0.292
AVN 202 186 53 0.331 1.207
(0.954–1.525)
0.117 1.206
(0.954–1.525)
0.118 1.133
(0.835–1.539)
0.423 1.796
(1.034–3.120)
0.038
IVS12-1667 G>A GG AG AA
(rs2267443) CTL 116 121 29 0.337
AVN 169 192 69 0.384 1.265
(1.006–1.590)
0.044 1.259
(1.003–1.579)
0.047 1.254
(0.916–1.718)
0.157 1.589
(0.996–2.535)
0.052
*11: homozygotes for the major allele, 12: heterozygotes and 22: homozygotes for the minor allele.
† Logistic regression analyses were used for calculating. bold: P value < 0.05B
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Table 3: Association of SREBP-2 gene polymorphisms between the AVN subgroup patients and controls
Loci Sub-group Genotype Allele 2 vs. 1 Codominant Heterozy Dominant Recessive
11 12 22 MAF (11 vs 12 vs 22)* 12 + 22 vs. 11 22 vs. 11 + 12
OR (95% CI) P† OR (95% CI) P† OR (95% CI) P† OR (95% CI) P†
TT CT CC
IVS1+8408 T>C Alc 74 102 30 0.393 0.764
(0.581–1.004)
0.054 0.759
(0.575–1.002)
0.052 0.744
(0.494–1.121)
0.157 0.629
(0.379–1.045)
0.073
(rs2267439) Idio 69 85 27 0.384 0.701
(0.532–0.923)
0.011 0.695
(0.525–0.920)
0.011 0.625
(0.417–0.937)
0.023 0.617
(0.368–1.034)
0.067
Ster 16 31 9 0.438 0.865
(0.560–1.335)
0.511 0.860
(0.553–1.339)
0.504 0.940
(0.479–1.844)
0.857 0.677
(0.301–1.523)
0.346
GG GT TT
IVS3-342 G>T Alc 115 74 16 0.259 1.017
(0.747–1.386)
0.914 1.016
(0.751–1.375)
0.916 1.021
(0.694–1.501)
0.917 1.022
(0.495–2.109)
0.954
(rs2269657) Idio 94 73 14 0.279 1.159
(0.855–1.570)
0.342 1.165
(0.855–1.589)
0.333 1.153
(0.785–1.695)
0.468 1.431
(0.675–3.030)
0.350
Ster 32 20 2 0.222 0.951
(0.568–1.592)
0.848 0.949
(0.561–1.604)
0.845 0.989
(0.527–1.858)
0.973 0.704
(0.150–3.297)
0.656B
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GG AG AA
IVS11+414 G>A Alc 95 84 25 0.328 1.241
(0.925–1.665)
0.150 1.244
(0.925–1.672)
0.149 1.143
(0.779–1.678)
0.493 2.037
(1.028–4.034)
0.041
(rs1052717) Idio 85 72 24 0.332 1.214
(0.910–1.621)
0.188 1.214
(0.909–1.621)
0.189 1.092
(0.747–1.598)
0.649 1.998
(1.055–3.783)
0.034
Ster 22 30 4 0.339 1.230
(0.778–1.945)
0.376 1.258
(0.775–2.042)
0.352 1.452
(0.782–2.695)
0.237 0.966
(0.295–3.163)
0.954
GG AG AA
IVS12-1667 G>A Alc 74 95 30 0.389 1.380
(1.036–1.837)
0.027 1.382
(1.036–1.844)
0.028 1.495
(1.007–2.220)
0.046 1.575
(0.877–2.828)
0.128
(rs2267443) Idio 73 71 31 0.380 1.236
(0.930–1.642)
0.144 1.226
(0.927–1.620)
0.153 1.126
(0.759–1.669)
0.556 1.763
(1.015–3.059)
0.044
Ster 22 26 8 0.375 1.334
0.849–2.094)
0.211 1.340
(0.849–2.114)
0.209 1.408
(0.749–2.647)
0.288 0.566
(0.637–3.852)
0.328
*11: homozygotes for the major allele, 12: heterozygotes and 22: homozygotes for the minor allele.
† Logistic regression analyses were used for calculating. bold: P value < 0.05
Table 3: Association of SREBP-2 gene polymorphisms between the AVN subgroup patients and controls (Continued)BMC Medical Genetics 2008, 9:94 http://www.biomedcentral.com/1471-2350/9/94
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Conclusion
In summary, this study is the first report showing an asso-
ciation of SREBP-2 polymorphisms with a susceptibility
to AVN. Future functional studies are needed to demon-
strate that variations of SREBP-2 contribute to the devel-
opment of AVN.
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